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Abstract
Streptococcus pyogenes (group A streptococcus) colonises skin and throat tissues resulting in a range of
benign and serious human diseases. Opsonisation and phagocytosis are important defence mechanisms
employed by the host to destroy group A streptococci. Antisera against the cell-surface M protein, of
which over 150 different types have been identified, are opsonic and contribute to disease protection . In
this issue of Molecular Microbiology, Sandin and colleagues have comprehensively analysed the regions
of M5 protein that contribute to phagocytosis resistance and opsonisation. Human plasma proteins
bound to M5 protein B- and C-repeats were shown to block opsonisation, an observation that needs to be
carefully considered for the development of M protein-derived vaccines. Whilst safe and efficacious
human group A streptococcal vaccines are not commercially available, candidate M protein-derived
vaccines have shown promise in murine vaccine models and a recent phase 1 human clinical trial.
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Summary

Streptococcus pyogenes (group A streptococcus) colonises skin and throat tissues resulting
in a range of benign and serious human diseases. Opsonisation and phagocytosis are
important defence mechanisms employed by the host to destroy group A streptococci.
Antisera against the cell-surface M protein, of which over 150 different types have been
identified, are opsonic and contribute to disease protection . In this issue of Molecular
Microbiology, Sandin and colleagues have comprehensively analysed the regions of M5
protein that contribute to phagocytosis resistance and opsonisation. Human plasma
proteins bound to M5 protein B- and C-repeats were shown to block opsonisation, an
observation that needs to be carefully considered for the development of M protein-derived
vaccines. Whilst safe and efficacious human group A streptococcal vaccines are not
commercially available, candidate M protein-derived vaccines have shown promise in
murine vaccine models and a recent phase 1 human clinical trial.

Group A streptococcus (Streptococcus pyogenes) is the etiological agent of a range of human
diseases including pharyngitis, impetigo, cellulitis, scarlet fever, bacteremia, toxic shock
syndrome and necrotising fasciitis. Additionally, repeated S. pyogenes infections may lead to the
development of the post-immune sequelae rheumatic fever, rheumatic heart disease and acute
post-streptococcal glomerulonephritis. Although some experimental purified subunit vaccines
against S. pyogenes are under development based on M protein, C5a peptidase, SpeB, group A
carbohydrate and the fibronectin binding proteins Sfb1, SOF and FBP54 (Brandt et al., 2000;
Courtney et al., 2003; Dale et al., 1999; Guzman et al., 1999; Ji et al., 1997; Kapur et al., 1994;
Kawabata et al., 2001; McArthur et al. 2005; Salvadori et al., 1995), an effective and safe GAS
vaccine is not available for human use.
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M protein exists as a dimer consisting of two polypeptide chains complexed into an alpha-helical
coiled-coil configuration that is anchored in the cell membrane. Each polypeptide may consist of
up to four repeat regions (labelled A-D) that vary in size and amino acid composition. The Cterminal end of the molecule (including the C-repeat region) is highly conserved among GAS
strains. The surface exposed N-terminal portion of M proteins usually consist of a hypervariable
region (encompassing the A-repeat region) and a semi-variable B-repeat region (Figure 1).
Antigenic differences in the hypervariable region of the protein formed the basis for the
Lancefield serological classification of GAS and has since been expanded upon through the
implementation of an emm typing system based on the sequencing of the N-terminal nucleotide
residues of the emm gene (which encodes M-protein). There are currently more than 150
recognised

emm

genotypes

(http://www.cdc.gov/ncidod/biotech/strep/emmtypes.htm).

Additionally, other surface proteins of GAS that are structurally similar to M-protein have been
characterised and are termed M-like proteins. These proteins differ in the types and numbers of
repeats. Functional studies have demonstrated the ability of M-like proteins to interact with a
variety human proteins including plasminogen (PAM) (Berge and Sjobring, 1993), IgG and IgA
(Arp, protein H, Mrp, Sir, Enn) (Frithz et al., 1989; Gomi et al., 1990; Stenberg et al., 1992;
Stenberg et al., 1994).

The antigenic heterogeneity displayed by various M-proteins has enabled it to evolve a number
of different functions. It has long been recognised that GAS can avoid phagocytosis-mediated
killing by interfering with the complement pathway. M proteins may play a role in this resistance
by binding regulatory components of the complement control system. The hypervariable region
of M-protein can bind both Factor H and Factor H-like protein (Johnsson et al., 1998), while the
C-repeat region can also bind Factor H (Kotarsky et al., 2001). The C-repeat regions of a number
of different M-proteins also bind human serum albumin (Akesson et al., 1994; Retnoningrum
and Cleary, 1994). The hypervariable region of M-protein may bind C4bp (Johnsson et al.,
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1996), which is an important regulator in the classical complement pathway, and contributes to
phagocytosis resistance (Berggard et al., 2001). Numerous M-protein types can bind fibrinogen
via the B-repeat region and, again, this property contributes to phagocytosis resistance (Ringdahl
et al., 2000).

Although research towards an effective vaccine for the prevention of GAS infections has been
pursued for over 70 years, a commercial vaccine is still not available. M-protein is a major
protective antigen of GAS and has been the focus for much of the vaccine research. Efforts to
develop an M protein-derived vaccine were hindered in the late 1960’s by the observation of an
increased prevalence of rheumatic fever in vaccinated versus control children in vaccine trials
using a crude M protein preparation (Massell et al., 1969). M-protein shares epitopes with a
number of host proteins including, cardiac and skeletal myosin, tropomyosin, laminin and keratin
(Cunningham, 2003). More recently, protective regions within the M-protein have been and
separate from the regions containing the cross-reactive epitopes responsible for the induction of
the autoimmune driven post-streptococcal sequelae. Two of the most promising approaches
include multivalent, type specific vaccines (Kotloff et al., 2004; McNeil et al., 2005) and peptide
based vaccines based on the C-repeat region of M-protein (Batzloff et al., 2003).

In this issue of Molecular Microbiology, Sandin et al. have examined domains of the M5 protein
for their capacity to promote resistance to phagocytosis under nonimmune conditions. These
authors have unequivocally demonstrated that the B-repeats, but neither the C-repeats nor the
amino-terminal hypervariable region, are required for phagocytosis resistance. However, in the
presence of human plasma proteins, only antibodies raised against the amino-terminal
hypervariable domain were able to opsonise M5 group A streptococci. The presence of human
fibrinogen inhibited the binding of specific antisera to the M5 B-repeats. Human fibrinogen was
found to bind the B-repeats in previous studies (Carlsson et al., 2005; Ringdahl et al., 2000).
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Similarly, antibodies raised against the M5 C-repeats failed to bind in the presence of human
serum albumin, which is capable of binding to the C-repeats (Akesson et al., 1994;
Retnoningrum and Cleary, 1994). The significance of these data rests in the fact that there are
more than 150 different M types and, thus, antisera specific to the hypervariable region of one M
type will not opsonise other M types. The direction of opsonising antibodies to the hypervariable
region of M protein and the protection of more highly conserved repeat regions of M protein
through binding to human serum proteins represents a highly evolved mechanism of immune
resistance for group A streptococci with important implications for the development of M
protein-based vaccines.

The M-protein family is extensive in group A streptococcus and exhibits a diverse range of
antigenic and functional properties. The study of Sandin et al. on M5 protein should be extended
to other members of the M-protein family that interact with other human proteins. Such studies
might also be broadly useful in conjunction with the examination of the vaccine potential of
adhesins and other microbial proteins able to bind human target molecules. Sandin et al. observe
that the phagocytosis assay used by them and others might only represent the situation
encountered during septicaemic infection. Whilst human plasma proteins might be present at
inflamed mucosal and skin infection sites, it remains to be determined whether specific
antibodies against the B- and C-repeats of M protein are inhibited from binding under these
conditions. In vivo confirmation and further investigation of this mechanism of immune evasion
might require the development of humanised transgenic mice expressing human serum albumin
and human fibrinogen. A transgenic mouse line expressing human plasminogen has already been
constructed to examine the role of the plasminogen activation system in invasive disease (Sun et
al., 2004; Walker et al., 2005).
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Following a long hiatus, several groups are beginning human trials of prototype M protein-based
vaccines. The definition of the relationship between binding of human serum proteins and
opsonisation capacity is an important consideration for such group A streptococcal vaccine
studies. Such work also has broader implications for selection and analysis of potential
protective antigens against other bacterial pathogens, in particular those able to bind human
proteins.

Figure legend

Figure 1. Structural and functional characteristics of M and M-like proteins. The molecule is
anchored in the group A streptococcal cell wall via the C terminus (Pro/Gly rich and
hydrophobic domains) and exists as a coiled coil structure (left). M protein consists of A-, B-, Cand D-repeats with capacity to bind several human plasma proteins as indicated (right). A- or Drepeats may not be present in some M or M-like proteins. Different M proteins have the capacity
to interact with only a subset of the human plasma proteins indicated. Adapted from Fischetti
(2000).
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